An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)

Roche

Status: Completed

Conditions: Colorectal Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01697462

ML22585

Details and patient eligibility

About

This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer. Patients will be followed until disease progression or unacceptable toxicity occurs.

Enrollment: 258 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Metastatic colorectal cancer
• Receiving Xeloda according to registered indication

Exclusion criteria

• Patients who are not eligible for Xeloda treatment according to the Summary of Product Characteristics

Trial design

258 participants in 1 patient group

Cohort